Nexalin Technology, Inc. (NXL)

1.3100 -0.0200 (-1.50%) 收市：04:00PM EDT

Nexalin Technology, Inc.

1776 Yorktown
Suite 550
Houston, TX 77056
United States
(832) 260-0222
https://www.nexalin.com

版塊: Healthcare
行業: Medical Devices
全職員工: 6

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Mark White	President, CEO, CFO & Director	442.5k	無	1962
Dr. David Owens M.D.	Chief Medical Officer & Director	42.8k	無	1961
Mr. Michael Nketiah	Senior Vice-President of Quality, Regulatory & Clinical Affairs	280k	無	1976
Ms. Marilyn Elson	Controller	382.72k	無	1953
Mr. John Patrick Claude	Co-Founder and Director of Engineering & Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

公司管治

截至 無 止，Nexalin Technology, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。